Abstract:Key PointsAttempts to target RAS pharmaceutically have not yet yielded small molecules with sufficient potency and drug-like characteristics to be useful, but additional approaches are underway.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.Inhibitors of RAS effector signalling are currently centred on the RAF–MEK–ERK and PI3K–AKT–TOR pathways, with many inhibitors of components of these two pathways under clinical evaluation. The less well-studied effector pathways that lead to activation of RAL and RAC small GTPases are also promising targets.Despite some setbacks owing to issues of reproducibility, functional screens for synthetic lethal interactors with oncogenic RAS remain an attractive approach to identify novel drug targets for RAS-driven cancers.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.

Drugging the Next Undruggable KRAS Allele-Gly12Asp

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

Drugging KRAS: current perspectives and state-of-art review

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

KRAS mutation: from undruggable to druggable in cancer

Mutant KRAS is a druggable target for pancreatic cancer

Targeting KRAS in cancer

Novel druggable space in human KRAS G13D discovered using structural bioinformatics and a P-loop targeting monoclonal antibody

Eliminating oncogenic RAS: back to the future at the drawing board

A New Approach to an Old Problem in Cancer Drug Development

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Drugging the undruggable RAS: Mission Possible?

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions

Abstract C099: Mutant-selective, covalent inhibitors of K-Ras(G12D)

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Targeting KRAS Mutant Cancers: from Druggable Therapy to Drug Resistance

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors